Overview

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2028-08-07

Target enrollment:

Participant gender:

Summary

This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over time. In the second part of the study tow medications will be taken and the dose of the medication may be changed to a higher dose.

Phase:

PHASE1

Details

Lead Sponsor:

Lei Zheng

Collaborator:

Biosin USA, Inc.

Treatments:

trastuzumab deruxtecan